menu

Mitigating MACE Risk in T2D & ASCVD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Mitigating MACE Risk in T2D & ASCVD

Mitigating MACE Risk in T2D & ASCVD

What strategies and guidelines can we use to reduce the risk of cardiovascular events in patients with both type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD)? Join leading experts in this four-part series to find out.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2022 Novo Nordisk All rights reserved.
US22DI00407 December 2022


Episodes 0-0 of 0

    Schedule14 Jul 2024